2-(4-(4-Aminobutyl)piperazin-1-yl)phenol | 927187-09-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(4-(4-Aminobutyl)piperazin-1-yl)phenol
• 英文别名: 2-[4-(4-aminobutyl)-1-piperazinyl]phenol；2-[4-(4-Aminobutyl)piperazin-1-yl]phenol
• CAS: 927187-09-5
• 化学式: C₁₄H₂₃N₃O
• 分子量: 249.356
• InChiKey: IZAUCUIZYGYRGF-UHFFFAOYSA-N

物化性质

• 沸点：
  400.3±45.0 °C(Predicted)
• 密度：
  1.105±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  52.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-(4-Aminobutyl)piperazin-1-yl)phenol 在 四丁基氢氧化铵 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.03h， 生成 N-[4-[4-(2-[¹⁸F]fluoroethoxyphenyl)piperazin-1-yl]butyl]-pyrazolo-[1,5-a]pyridin-2-carboxamide
  参考文献：
  名称：

  Development of molecular tools based on the dopamine D3 receptor ligand FAUC 329 showing inhibiting effects on drug and food maintained behavior

  摘要：

  Dopamine D-3 receptor-mediated networks have been associated with a wide range of neuropsychiatric diseases, drug addiction and food maintained behavior, which makes D-3 a highly promising biological target. The previously described dopamine D-3 receptor ligand FAUC 329 (1) showed protective effects against dopamine depletion in a MPTP mouse model of Parkinson's disease. We used the radioligand [F-18]2, a [(18)]fluoroethoxy substituted analog of the lead compound 1 as a molecular tool for visualization of D-3-rich brain regions including the islands of Calleja. Furthermore, structural modifications are reported leading to the pyrimidylpiperazine derivatives 3 and 9 displaying superior subtype selectivity and preference over serotonergic receptors. Evaluation of the lead compound 1 on cocaine-seeking behavior in non-human primates showed a substantial reduction in cocaine self-administration behavior and food intake. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2017.04.036
• 作为产物：
  描述：

  1-(2-羟基苯基)哌嗪 在 lithium aluminium tetrahydride 、 potassium carbonate 、 potassium iodide 作用下， 以 四氢呋喃 、 乙醚 、 丙酮 为溶剂， 反应 21.0h， 生成 2-(4-(4-Aminobutyl)piperazin-1-yl)phenol
  参考文献：
  名称：

  Development of molecular tools based on the dopamine D3 receptor ligand FAUC 329 showing inhibiting effects on drug and food maintained behavior

  摘要：

  Dopamine D-3 receptor-mediated networks have been associated with a wide range of neuropsychiatric diseases, drug addiction and food maintained behavior, which makes D-3 a highly promising biological target. The previously described dopamine D-3 receptor ligand FAUC 329 (1) showed protective effects against dopamine depletion in a MPTP mouse model of Parkinson's disease. We used the radioligand [F-18]2, a [(18)]fluoroethoxy substituted analog of the lead compound 1 as a molecular tool for visualization of D-3-rich brain regions including the islands of Calleja. Furthermore, structural modifications are reported leading to the pyrimidylpiperazine derivatives 3 and 9 displaying superior subtype selectivity and preference over serotonergic receptors. Evaluation of the lead compound 1 on cocaine-seeking behavior in non-human primates showed a substantial reduction in cocaine self-administration behavior and food intake. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2017.04.036

文献信息

• [EN] PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR)<br/>[FR] PHENYL CARBAMATES ET LEUR UTILISATION COMME INHIBITEURS DE L'ENZYME HYDROLASE D'AMIDES D'ACIDES GRAS (FAAH) ET MODULATEURS DU RÉCEPTEUR D3 DE LA DOPAMINE (D3DR)
  申请人：FOND ISTITUTO ITALIANO DI TECNOLOGIA

  公开号：WO2015007615A1

  公开（公告）日：2015-01-22

  The invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof wherein Ar', R1, R2, R3, R4, X, Y are as defined in the description of invention, as multi-target directed ligands (MTDLs) that are at the same time inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR), their methods of preparation, formulations and therapeutic applications thereof.

  该发明提供了式（I）的化合物或其药用可接受的盐，其中Ar'，R1，R2，R3，R4，X，Y如发明描述中所定义，作为多靶点定向配体（MTDLs），同时是脂肪酸酰胺水解酶（FAAH）酶的抑制剂和D3多巴胺受体（D3DR）的调节剂，以及它们的制备方法、配方和治疗应用。
• Design, synthesis, and evaluation of N-(4-(4-phenyl piperazin-1-yl)butyl)-4-(thiophen-3-yl)benzamides as selective dopamine D3 receptor ligands
  作者：Peng-Jen Chen、Michelle Taylor、Suzy A. Griffin、Armaghan Amani、Hamed Hayatshahi、Kenneth Korzekwa、Min Ye、Robert H. Mach、Jin Liu、Robert R. Luedtke、John C. Gordon、Benjamin E. Blass

  DOI：10.1016/j.bmcl.2019.07.020

  日期：2019.9

  As part of our on-going effort to explore the role of dopamine receptors in drug addiction and identify potential novel therapies for this condition, we have a identified a series of N-(4-(4-phenyl piperazin-1-yl)butyl)-4-(thiophen-3-yl)benzamide D3 ligands. Members of this class are highly selective for D3 versus D2, and we have identified two compounds (13g and 13r) whose rat in vivo IV pharmacokinetic

  为了探索多巴胺受体在药物成瘾中的作用并确定针对这种情况的潜在新疗法，我们正在进行的工作包括确定一系列N-（4-（4-苯基哌嗪-1-基）丁基）-4-（噻吩-3-基）苯甲酰胺D 3配体。该类别的成员对D 3和D 2具有高度选择性，并且我们鉴定了两种化合物（13g和13r），它们的大鼠体内IV药代动力学特性表明它们适用于评估物质使用失调的体内功效模型。
• An Interactive SAR Approach to Discover Novel Hybrid Thieno Probes as Ligands for D2-Like Receptors with Affinities in the Subnanomolar Range
  作者：Mohamed A. O. Abdel-Fattah、Jochen Lehmann、Ashraf H. Abadi

  DOI：10.1002/cbdv.201300204

  日期：2013.12

  ,3-dione derivatives was synthesized to serve as probes for dopaminergic receptors. Among this series, compound 6a showed the highest affinity towards D4 and D3 receptors with Ki values in the low nanomolar range, and D2/D4- and D2/D3-selectivity indices of 72 and 20, respectively. Optimization rounds were adopted and led to the D4-selective ligand thiophene-2-carboxamide 9a with a Ki (D4) value of

  合成了一系列的[（苯基哌嗪基）烷基]-异吲哚-1,3-二酮衍生物，用作多巴胺能受体的探针。在该系列中，化合物6a对D4和D3受体的亲和力最高，Ki值在低纳摩尔范围内，D2 / D4-和D2 / D3-选择性指数分别为72和20。采用最优化回合，得到Ki（D4）值为0.62 nM的D4选择性配体噻吩-2-羧酰胺9a，其丁基类似物10a的Ki（D4）和Ki（D3）值为0.03和0.26 nM。对接实验揭示了独特的D4残基Arg186在操纵配体D4亚型受体选择性中的重要性。
• Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands with optimal lipophilicity for brain imaging of the dopamine D3 receptor. Part II
  作者：Marcello Leopoldo、Enza Lacivita、Paola De Giorgio、Marialessandra Contino、Francesco Berardi、Roberto Perrone

  DOI：10.1016/j.bmc.2008.11.044

  日期：2009.1

  In the search for compounds with potential for development as positron emission tomography radioligands for brain D3 receptor imaging, a series of N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides with appropriate lipophilicity (2 < log P < 3.5) were synthesized and tested in vitro. Some of the final compounds showed moderate-to-high dopamine D3 receptor affinities but lacked selectivity over D2 receptors

  在寻找具有潜力开发为脑D 3受体成像的正电子发射断层照相放射配体的化合物时，一系列具有适当亲脂性的N- [4-（4-芳基哌嗪-1-基）丁基]芳基羧酰胺（2
• NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME
  申请人：Sokoloff Pierre

  公开号：US20100029682A1

  公开（公告）日：2010-02-04

  The present invention relates to novel chromene or thiochromene carboxamide derivatives, the preparation of same, pharmaceutical compositions of same and the use of same as dopamine D3 ligands as a medicament for central nervous system disorders.

  本发明涉及新型香豆素或硫代香豆素羧酰胺衍生物、其制备方法、相应的药物组成物以及将其用作中枢神经系统疾病的多巴胺D3受体配体的药物。